share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:拟议出售证券

SEC announcement ·  03/04 17:54
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,903 shares of common stock on 03/04/2024, with an aggregate market value of $165,739. The shares to be sold were recently acquired through restricted stock vesting on 03/01/2024 and 03/03/2024, totaling 14,903 shares. This transaction follows a recent sale of 2,465 shares by Watanabe on 02/28/2024, which grossed $26,129.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,903 shares of common stock on 03/04/2024, with an aggregate market value of $165,739. The shares to be sold were recently acquired through restricted stock vesting on 03/01/2024 and 03/03/2024, totaling 14,903 shares. This transaction follows a recent sale of 2,465 shares by Watanabe on 02/28/2024, which grossed $26,129.
Arcutis Biotherapeutics, Inc.高管渡边托德·富兰克林定于2024年4月3日出售14,903股普通股,总市值为165,739美元。拟出售的股票最近于2024年1月3日和2024年3月3日通过限制性股票归属收购,共计14,903股。该交易是在渡边最近于2024年2月28日出售了2465股股票之后进行的,总收入为26,129美元。
Arcutis Biotherapeutics, Inc.高管渡边托德·富兰克林定于2024年4月3日出售14,903股普通股,总市值为165,739美元。拟出售的股票最近于2024年1月3日和2024年3月3日通过限制性股票归属收购,共计14,903股。该交易是在渡边最近于2024年2月28日出售了2465股股票之后进行的,总收入为26,129美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息